TEST:

GALEAS® Bladder

This is a proof-of-principle study, rather than definitive evidence of utility as a companion diagnostic, with the need for fusion detection validation in larger patient cohorts. In addition to BC detection, a modified version of GB demonstrates feasibility for tissue and urine-based detection of FGFR3 fusions.

"Nonacus, has invested in two West Midlands-based trials of an at-home urine test to prove its effectiveness in detecting bladder cancer, which affects more than 100,000 people in the UK...The trials use the Galeas Bladder genetic test, which a previous study—funded by Cancer Research UK and the Medical Research Council—found to accurately and consistently detect bladder cancer from a urine sample. "

"GALEAS™ Bladder, our urine test for the non-invasive detection and monitoring of bladder cancer, has appeared in the European Association of Urology (EAU) Guidelines on Non-Muscle-Invasive Bladder Cancer in a surveillance setting."

"GALEAS™ Bladder, our urine test for the non-invasive detection and monitoring of bladder cancer, has appeared in the European Association of Urology (EAU) Guidelines on Non-Muscle-Invasive Bladder Cancer in a surveillance setting. The Guidelines are developed by the EAU as best practice clinical guidelines primarily for frontline urologists across Europe, but also for patients to support shared decision making. "

"New collaboration with Nonacus Clinical Services enables The London Clinic to offer patients a non-invasive means to test for bladder cancer...Nonacus Clinical Services...is working with The London Clinic to help more patients benefit from its non-invasive GALEAS™ Bladder test for cancer."

Our data show that, with a comprehensive mutation panel, any gains from adding methylation markers are, at best, marginal. It is likely that low tumour content is the commonest cause of false-negative urine test results. Our study does have a limited sample size and other methylation markers might behave differently to the those studied here.

"Genomic testing laboratory Informed Genomics said...that it has formed a partnership with five UK National Health Service Trusts to compare the performance of the company's bladder cancer testing service against the standard-of-care cystoscopy...All patients in the study will receive cystoscopies as well as provide a urine sample for testing using Galeas Bladder. The results will be compared to determine the sensitivity and specificity of the urine-based test."

"Nonacus...will launch GALEAS® Bladder, a novel test for the non-invasive detection of bladder cancer at the European Association of Urology (EAU) Annual Meeting, taking place in Milan, March 10-13th 2023...Developed in collaboration with Professor Rik Bryan and Dr Doug Ward at the University of Birmingham UK, GALEAS® Bladder has been validated in over 600 patient samples from 3 UK clinical cohorts. Analyses confirmed the performance of GALEAS® Bladder, showing high diagnostic accuracy (sensitivity >90%, specificity >85%) and good performance across all grades and stages of bladder cancer."